Glaucoma Therapy Advances

Glaucoma is primarily managed with prescription eye drops. If a patient’s glaucoma progresses or the patient stops responding to the eye drops, a surgical solution is offered.

These surgical solutions are often highly invasive, require long recovery times, and could result in long-term complications.

As technology has progressed, less invasive techniques have emerged that have improved the safety profile for glaucoma surgery. This opened more surgical options for patients interested in effective glaucoma management which does not rely solely on the continuous use of prescription medication.

A Revolution in Glaucoma Therapy

With the FDA approval of the iStent®, Micro-Invasive Glaucoma Surgery (MIGS) became a preferred approach to glaucoma management for many eye care professionals and their patients with mild-to-moderate glaucoma. 1

Now, with the FDA approval of iStent inject® – the next-generation Glaukos trabecular micro-bypass technology – Glaukos is advancing the standard of care for glaucoma patients.

Performed at the time of cataract surgery, iStent inject® has proven to be effective in decreasing IOP, with an excellent safety profile, few complications, and fast recovery time.2, 3

iStent inject® may also reduce patients’ need for medications as determined by an eye care professional. The majority of patients who received iStent inject® in the U.S. pivotal trial were medication-free at 23 months. 2 Other benefits associated with this innovative treatment include:

• Minimally traumatic to delicate eye tissue
• Effectively lowers IOP
• Excellent safety profile
• Rapid recovery